Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DVS · 4 trials · 2 indications
A TEAE was defined as an event that was absent before treatment and emerged or worsened during the treatment period.
A TEAE was defined as an event that was absent before treatment and emerged or worsened during the treatment period.
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.
| Arm | Type | Description |
|---|---|---|
| Desvenlafaxine Succinate Sustained-Release | EXPERIMENTAL | - |
| A | EXPERIMENTAL | DVS SR 50mg/day |
| B | EXPERIMENTAL | DVS SR 100mg/day |
| C | EXPERIMENTAL | DVS SR 200mg/day |
| D | ACTIVE_COMPARATOR | Paroxetine 20mg/day |
| Name | Type | Description |
|---|---|---|
| DVS SR | DRUG | Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator |
| Paroxetine | DRUG | 20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper |
| DVS-SR 50 mg | DRUG | - |
| DVS-SR 100 mg | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Completed study B2061032 and who in the investigator's opinion, would benefit from long term treatment with DVS SR * Willingness and ability to comply with scheduled visits, treatment plan, and procedures Exclusion Criteria: * Requires precaution against suicide * Not in gen...
DVS, also known as desvenlafaxine sustained-release, is an investigational small molecule being studied for the treatment of Major Depressive Disorder (MDD) in adult, child, and adolescent outpatients. It is being developed by Pfizer, Inc. (NYSE: PFE) and has completed Phase 3 clinical trials for this psychiatric condition.
DVS is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by blocking the reuptake of serotonin and norepinephrine in the brain, thereby increasing their levels in the synaptic cleft. This mechanism is believed to contribute to its antidepressant effects in treating Major Depressive Disorder.
DVS is being developed by Pfizer, Inc., a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer has conducted multiple Phase 3 clinical trials evaluating DVS for the treatment of Major Depressive Disorder across various patient populations.
DVS is in Phase 3 clinical development. All three Phase 3 trials for DVS have been completed, with a total enrollment of 1,032 participants. These trials were randomized, double-blind, and active-controlled, studying the drug's efficacy and safety in treating Major Depressive Disorder.
DVS has completed three Phase 3 trials: NCT00277823 (480 adults with MDD in the US), NCT00445679 (807 adults with MDD in China, India, South Korea, and Taiwan), and NCT01371708 (283 children and adolescents with MDD in the US and Chile). An additional trial, NCT01371721, enrolled 269 pediatric patients.
Yes, DVS is the same as desvenlafaxine sustained-release (DVS-SR). The drug is referred to as DVS in clinical trial documentation, and it is being studied as a treatment for Major Depressive Disorder in both adult and pediatric populations.